Publikationer av Burcu Ayoglu
Refereegranskade
Artiklar
[1]
A. Sountoulidis et al., "A topographic atlas defines developmental origins of cell heterogeneity in the human embryonic lung," Nature Cell Biology, 2023.
[2]
M. Signorelli et al., "Penalized regression calibration : A method for the prediction of survival outcomes using complex longitudinal and high-dimensional data," Statistics in Medicine, vol. 40, no. 27, s. 6178-6196, 2021.
[3]
D. Mahdessian et al., "Spatiotemporal dissection of the cell cycle with single-cell proteogenomics," Nature, vol. 590, no. 7847, 2021.
[4]
K. Strandberg et al., "Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy," Journal of Neuromuscular Diseases, vol. 7, no. 3, s. 231-246, 2020.
[5]
M. Signorelli et al., "Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy," Journal of Cachexia, Sarcopenia and Muscle, vol. 11, no. 2, s. 505-517, 2020.
[6]
K. Tengvall et al., "Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk," Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 34, s. 16955-16960, 2019.
[7]
S. K. Bedri et al., "Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment," PLOS ONE, vol. 14, no. 5, 2019.
[8]
C. Ge et al., "Structural Basis of Cross-Reactivity of Anti-Citrullinated Protein Antibodies," Arthritis & Rheumatology, vol. 71, no. 2, s. 210-221, 2019.
[9]
B. Liang et al., "The autoantibody response to cyclic citrullinated collagen type II peptides in rheumatoid arthritis," Rheumatology, vol. 58, no. 9, s. 1623-1633, 2019.
[10]
[11]
P. Reuterswärd et al., "Levels of human proteins in plasma associated with acute paediatric malaria," Malaria Journal, vol. 17, 2018.
[12]
B. Omazic et al., "A Preliminary Report : Radical Surgery and Stem Cell Transplantation for the Treatment of Patients with Pancreatic Cancer," Journal of immunotherapy (1997), vol. 40, no. 4, s. 132-139, 2017.
[13]
C. P. Ge et al., "Anti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage," JCI INSIGHT, vol. 2, no. 13, 2017.
[14]
L. Lourido et al., "Discovery of circulating proteins associated to knee radiographic osteoarthritis," Scientific Reports, vol. 7, 2017.
[15]
A. Lourbakos et al., "Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne," Scientific Reports, vol. 7, 2017.
[16]
A. Zandian et al., "Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy," Journal of Proteome Research, vol. 16, no. 3, s. 1300-1314, 2017.
[17]
B. Ayoglu et al., "Anoctamin 2 identified as an autoimmune target in multiple sclerosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 8, s. 2188-2193, 2016.
[18]
B. Ayoglu, J. M. Schwenk och P. Nilsson, "Antigen arrays for profiling autoantibody repertoires," Bioanalysis, vol. 8, no. 10, s. 1105-1126, 2016.
[19]
R. Sjöberg et al., "Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling," New Biotechnology, vol. 33, no. 5, s. 582-592, 2016.
[20]
B. Ayoglu et al., "Multiplexed protein profiling by sequential affinity capture," Proteomics, vol. 16, no. 8, s. 1251-1256, 2016.
[21]
S. Byström et al., "Affinity Proteomic Profiling of Plasma, Cerebrospinal Fluid, and Brain Tissue within Multiple Sclerosis," Journal of Proteome Research, vol. 13, no. 11, s. 4607-4619, 2014.
[22]
B. Ayoglu et al., "Affinity proteomics within rare diseases : a BIO-NMD study for blood biomarkers of muscular dystrophies," EMBO Molecular Medicine, vol. 6, no. 7, s. 918-936, 2014.
[23]
B. Ayoglu et al., "Bead Arrays for Antibody and Complement Profiling Reveal Joint Contribution of Antibody Isotypes to C3 Deposition," PLOS ONE, vol. 9, no. 5, s. e96403, 2014.
[24]
A. N. Kremer et al., "Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation," Haematologica, vol. 99, no. 2, s. 365-369, 2014.
[25]
A. Häggmark et al., "Antibody-based profiling of cerebrospinal fluid within multiple sclerosis," Proteomics, vol. 13, no. 15, s. 2256-2267, 2013.
[26]
B. Ayoglu et al., "Autoantibody profiling in multiple sclerosis using arrays of human protein fragments," Molecular & Cellular Proteomics, vol. 12, no. 9, s. 2657-2672, 2013.
[27]
B. Ayoglu et al., "Systematic antibody and antigen-based proteomic profiling with microarrays," EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, vol. 11, no. 2, s. 219-234, 2011.
Kapitel i böcker
[28]
R. Sjöberg et al., "High-density antigen microarrays for the assessment of antibody selectivity and off-target binding," i Epitope Mapping Protocols, : Humana Press Inc., 2018, s. 231-238.
[29]
B. Ayoglu, P. Nilsson och J. M. Schwenk, "Multiplexed antigen bead arrays for the assessment of antibody selectivity and epitope mapping," i Epitope Mapping Protocols, : Humana Press Inc., 2018, s. 239-248.
[30]
E. Birgersson, J. . M. Schwenk och B. Ayoglu, "Bead-based and multiplexed immunoassays for protein profiling via sequential affinity capture," i Serum/Plasma Proteomics, : Humana Press, 2017, s. 45-54.
Icke refereegranskade
Artiklar
[31]
C. Gnann et al., "Deep immunological profiling of the murine brain and spleen after high fat diet by CODEX multiplexed imaging.," Molecular Biology of the Cell, vol. 29, no. 26, 2018.
[32]
T. Olsson et al., "Molecular mimicry between the autoantigen Anoctamin 2 and Epstein Barr virus nuclear antigen 1 associates with increased risk for multiple sclerosis," Multiple Sclerosis Journal, vol. 24, s. 64-64, 2018.
[33]
B. Ayoglu et al., "Anoctamin 2 identified as an autoimmune target in multiple sclerosis," Multiple Sclerosis Journal, vol. 22, s. 10-10, 2016.
[34]
B. Ayoglu et al., "Anoctamin 2 identified as an autoimmune target in multiple sclerosis," European Journal of Neurology, vol. 23, s. 57-57, 2016.
[35]
L. Lourido et al., "IDENTIFICATION OF A SERUM PROTEIN BIOMARKER PANEL FOR THE DIAGNOSIS OF KNEE OSTEOARTHRITIS," Osteoarthritis and Cartilage, vol. 24, s. S23-S23, 2016.
[36]
L. Lourido et al., "DISCOVERY OF POTENTIAL SERUM BIOMARKERS IN OSTEOARTHRITIS USING PROTEIN ARRAYS," Annals of the Rheumatic Diseases, vol. 74, s. 373-374, 2015.
[37]
L. Lourido et al., "Discovery of Novel Serum Biomarkers for Osteoarthritis Using Affinity Proteomics," Arthritis & Rheumatology, vol. 67, 2015.
[38]
B. Ayoglu et al., "Anoctamin 2, a novel autoimmune target candidate in multiple sclerosis," Multiple Sclerosis Journal, vol. 20, s. 49-50, 2014.
[39]
J. C. van der Griendt et al., "Antibodies against intracellular antigens develop as a result of tissue damage induced by donor lymphocyte infusion after allogeneic stem cell transplantation," Immunology, vol. 137, s. 737-737, 2012.
[40]
B. Ayoglu et al., "Proteomic profiling of the autoimmunity repertoire in multiple sclerosis," New Biotechnology, vol. 29, s. S20-S20, 2012.
[41]
J. C. van der Griendt et al., "High Throughput Screening for Antibody Responses Against H-Y Antigens and Their X-Variants in Allogeneic Hematopoeietic Stem Cell Transplantation," Blood, vol. 118, no. 21, s. 1749-1750, 2011.
Avhandlingar
[42]
B. Ayoglu, "Affinity Arrays for Profiling Proteins and Autoantibody Repertoires," Doktorsavhandling Stockholm : KTH Royal Institute of Technology, TRITA-BIO-Report, 2014:12, 2014.
Övriga
[43]
R. Sjöberg et al., "Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling," (Manuskript).
[44]
S. Sariyar et al., "High-parametric protein maps reveal the spatial organization in early-developing human lung," (Manuskript).
[45]
P. Reuterswärd et al., "Levels of human proteins in plasma as indicators for acute severe pediatric malaria," (Manuskript).
[46]
D. Mahdessian et al., "Spatiotemporal dissection of the cell cycle regulated human proteome," (Manuskript).
[47]
B. Ayoglu et al., "The calcium-activated chloride channel anoctamine 2 as an autoimmune component of multiple sclerosis," (Manuskript).
Senaste synkning med DiVA:
2024-04-26 01:02:51